Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer

Mostert, Bianca; Sleijfer, Stefan; Foekens, John A.; Gratama, Jan W.

doi:10.1016/j.ctrv.2009.03.004

Cited by 255 publications

(181 citation statements)

References 135 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…The enumeration of circulating tumor cells (CTCs) in the peripheral blood of cancer patients is a promising tool to detect and monitor cancer earlier and less invasively than conventional methods [2,3]. In recent years, several assays to detect CTCs have been introduced [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146

Mostert

Kraan

Vries

et al. 2010

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

PurposeMost assays to detect circulating tumor cells (CTCs) rely on EpCAM expression on tumor cells.Recently, our group reported that in contrast to other molecular breast cancer subtypes, "normallike" cell lines lack EpCAM expression and are thus missed when CTCs are captured with EpCAM-based technology [1]. Here, the use of CD146 is introduced to detect EpCAM-negative CTCs, thereby improving CTC detection. Methods CD146and EpCAM expression were assessed in our panel of 41 breast cancer cell lines. Cells from 14 cell lines, 9 of which normal-like, were spiked into healthy donor blood. Using CellSearch™ technology, 7.5 mL whole blood was enriched for CTCs by adding ferrofluids loaded with antibodies against EpCAM and/or CD146 followed by staining for Cytokeratin and DAPI. Hematopoietic cells and circulating endothelial cells (CECs) were counterstained with CD45 and CD34, respectively. A similar approach was applied for blood samples of 20 advanced breast cancer patients. ResultsEight of 9 normal-like breast cancer cell lines lacked EpCAM expression but did express CD146.Five of these 8 could be adequately recovered by anti-CD146 ferrofluids. Of 20 advanced breast cancer patients whose CTCs were enumerated with anti-EpCAM and anti-CD146 ferrofluids, 9 had CD146+ CTCs. ConclusionsCells from breast cancer cell lines that lack EpCAM expression frequently express CD146 and can be recovered by anti-CD146 ferrofluids. CD146+ CTCs are present in the peripheral blood of breast cancer patients with advanced disease. Combined use of anti-CD146 and anti-EpCAM is likely to improve CTC detection in breast cancer patients.3

show abstract

Section: Introductionmentioning

confidence: 99%

“…In recent years, several assays to detect CTCs have been introduced [3]. CTCs measured with the FDA-approved CellSearch technique (Veridex™, Raritan, NJ) have prognostic value in metastatic breast cancer [4,5] and changes in CTC counts during systemic therapy can serve as early marker for response [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146

Mostert

Kraan

Vries

et al. 2010

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, a stringent quality control has to be applied during the whole procedure, including use of reference guidelines, positive and negative controls, optimal sample quality and primer selection, adequate instrument care, and analytical sensitivity and specificity (99)(100)(101)(102)(103). If all of these steps are conducted carefully, reliable quantitative data can be obtained, which could in term lead to a personalized medicine (97), and even further: a detection of CTCs in early stage cancer could influence the application of different treatment options (104,105).…”

Section: Ctc Detectionmentioning

confidence: 99%

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

et al. 2016

View full text Add to dashboard Cite

“…Since RNA is unstable and therefore disappears quickly from the blood after cell death, presence of RNA must be due to the occurence of viable tumor cells (Mostert et al, 2009). The RNA markers commonly used in CRC are carcinoembryonic antigen (CEA), CK19 and CK20 (Sergeant et al, 2008).…”

Section: Detection Of Dtcs By Rt-pcrmentioning

confidence: 99%

Cytokeratin 18 (CK18) and CK18 Fragments for Detection of Minimal Residual Disease in Colon Cancer Patients

Olszewski-Hamilton¹,

Buxhofer-Ausch²,

Hamilton³

2012

Cytokeratins - Tools in Oncology

View full text Add to dashboard Cite

Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer

Cited by 255 publications

References 135 publications

Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146

Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146

Real-time RT-PCR systems for CTC detection from blood samples of breast cancer and gynaecological tumour patients (Review)

Cytokeratin 18 (CK18) and CK18 Fragments for Detection of Minimal Residual Disease in Colon Cancer Patients

Contact Info

Product

Resources

About